[go: up one dir, main page]

WO2002045753A3 - Oral extended release formulation of gepirone - Google Patents

Oral extended release formulation of gepirone Download PDF

Info

Publication number
WO2002045753A3
WO2002045753A3 PCT/EP2001/014189 EP0114189W WO0245753A3 WO 2002045753 A3 WO2002045753 A3 WO 2002045753A3 EP 0114189 W EP0114189 W EP 0114189W WO 0245753 A3 WO0245753 A3 WO 0245753A3
Authority
WO
WIPO (PCT)
Prior art keywords
amount
gepirone
extended release
formulation
release formulation
Prior art date
Application number
PCT/EP2001/014189
Other languages
French (fr)
Other versions
WO2002045753A2 (en
Inventor
Johannes Gerardus Jos Egberink
John Francis Engelhart
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA03005099A priority Critical patent/MXPA03005099A/en
Priority to SK694-2003A priority patent/SK6942003A3/en
Priority to BR0115976-3A priority patent/BR0115976A/en
Priority to AU2002226371A priority patent/AU2002226371A1/en
Priority to JP2002547535A priority patent/JP2004517083A/en
Priority to KR10-2003-7007555A priority patent/KR20040018314A/en
Priority to PL01362445A priority patent/PL362445A1/en
Priority to HU0401021A priority patent/HUP0401021A2/en
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Priority to CA002436692A priority patent/CA2436692A1/en
Priority to EP01995688A priority patent/EP1343504A2/en
Priority to IL15585501A priority patent/IL155855A0/en
Publication of WO2002045753A2 publication Critical patent/WO2002045753A2/en
Publication of WO2002045753A3 publication Critical patent/WO2002045753A3/en
Priority to NO20032581A priority patent/NO20032581L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention makes a pharmaceutical formulation for oral administration with extended release properties available comprising an amount of gepirone hydrochloride, an amount of a cellulosic polymer matrix and an amount of microcrystalline cellulose characterised in that the amount the pharmaceutically acceptable cellulosic polymer matrix is from 70 to 85 wt%, the amount of carbohydrate binder is from 7 to 10 wt% and the amount of gepirone hydrochloride is from 13 to 21 wt%. The formulation is useful for a treatment for depression or a related central nervous system disorder with gepirone administered in a once-a-day oral formulation for extended release of gepirone.
PCT/EP2001/014189 2000-12-08 2001-11-30 Oral extended release formulation of gepirone WO2002045753A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PL01362445A PL362445A1 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone
BR0115976-3A BR0115976A (en) 2000-12-08 2001-11-30 Pharmaceutical formulation and treatment for depression or for a central nervous system disorder
AU2002226371A AU2002226371A1 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone
JP2002547535A JP2004517083A (en) 2000-12-08 2001-11-30 Oral sustained release formulation of Jepilone
KR10-2003-7007555A KR20040018314A (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone
MXPA03005099A MXPA03005099A (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone.
EP01995688A EP1343504A2 (en) 2000-12-08 2001-11-30 Pharmaceutical formulation of gepirone for oral administration
HU0401021A HUP0401021A2 (en) 2000-12-08 2001-11-30 Oral pharmaceutical composition containing gepiron
CA002436692A CA2436692A1 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone
SK694-2003A SK6942003A3 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone
IL15585501A IL155855A0 (en) 2000-12-08 2001-11-30 Pharmaceutical formulation of gepirone for oral administration
NO20032581A NO20032581L (en) 2000-12-08 2003-06-06 Pharmaceutical formulation of gepirone for oral administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00204388 2000-12-08
EP00204388.3 2000-12-08

Publications (2)

Publication Number Publication Date
WO2002045753A2 WO2002045753A2 (en) 2002-06-13
WO2002045753A3 true WO2002045753A3 (en) 2002-08-29

Family

ID=8172397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/014189 WO2002045753A2 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone

Country Status (19)

Country Link
EP (1) EP1343504A2 (en)
JP (1) JP2004517083A (en)
KR (1) KR20040018314A (en)
CN (1) CN1479620A (en)
AR (1) AR031461A1 (en)
AU (1) AU2002226371A1 (en)
BR (1) BR0115976A (en)
CA (1) CA2436692A1 (en)
CZ (1) CZ20031589A3 (en)
EC (1) ECSP034627A (en)
HU (1) HUP0401021A2 (en)
IL (1) IL155855A0 (en)
MX (1) MXPA03005099A (en)
NO (1) NO20032581L (en)
PL (1) PL362445A1 (en)
RU (1) RU2003120446A (en)
SK (1) SK6942003A3 (en)
WO (1) WO2002045753A2 (en)
ZA (1) ZA200303915B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028507A1 (en) * 2002-09-24 2004-04-08 Akzo Nobel N.V. Method to improve pharmaceutical tablets having a matrix of cellulose ether
MX2007005368A (en) * 2004-11-05 2007-09-11 Fabre Kramer Holdings Inc High-dosage extended-release formulation of gepirone.
MY198454A (en) * 2017-07-26 2023-08-29 Abbott Lab Nutritional Tablets and Methods of Making the Same
CN109745323A (en) * 2017-11-01 2019-05-14 四川科瑞德制药股份有限公司 Azapirone compound improves the active purposes of parasympathetic nerve

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700680A1 (en) * 1994-09-06 1996-03-13 Bristol-Myers Squibb Company Gepirone dosage form

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700680A1 (en) * 1994-09-06 1996-03-13 Bristol-Myers Squibb Company Gepirone dosage form

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FEIGER A.D.: "A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.", PSYCHOPHARMACOLOGY BULLETIN, (1996) 32/4 (659-665)., XP001069219 *
WILCOX C.S.: "A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients", PSYCHOPHARMACOLOGY BULLETIN, (1996) 32/3 (335-342)., XP001069224 *

Also Published As

Publication number Publication date
CN1479620A (en) 2004-03-03
ZA200303915B (en) 2004-08-20
AR031461A1 (en) 2003-09-24
PL362445A1 (en) 2004-11-02
EP1343504A2 (en) 2003-09-17
CZ20031589A3 (en) 2003-11-12
NO20032581D0 (en) 2003-06-06
CA2436692A1 (en) 2002-06-13
BR0115976A (en) 2003-12-30
SK6942003A3 (en) 2003-10-07
RU2003120446A (en) 2005-02-20
ECSP034627A (en) 2004-09-28
MXPA03005099A (en) 2004-02-12
IL155855A0 (en) 2003-12-23
WO2002045753A2 (en) 2002-06-13
KR20040018314A (en) 2004-03-03
AU2002226371A1 (en) 2002-06-18
NO20032581L (en) 2003-06-06
JP2004517083A (en) 2004-06-10
HUP0401021A2 (en) 2004-09-28

Similar Documents

Publication Publication Date Title
EP1649851A3 (en) Pregelatinized starch in a controlled release formulation
AU4121297A (en) Galenic form with extended release of milnacipran
WO2004010998A8 (en) Sustained-release tablet comprising reboxetine
WO2003013433A3 (en) Sequestered antagonist formulations
ATE333265T1 (en) RAPIDLY DISSOLVING SOLID DOSAGE FORMS FOR ORAL APPLICATION
CA2352211A1 (en) Sustained release matrix systems for highly soluble drugs
MXPA02005562A (en) Pharmaceutical superdisintegrant.
WO2004098564A3 (en) Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
CA2157323A1 (en) Gepirone dosage form
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
AU5673399A (en) Compositions and methods for treating intracellular infections
WO2002045753A3 (en) Oral extended release formulation of gepirone
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
US6524617B1 (en) Synergistic filler composition
US6589996B2 (en) Treatment of disorders relating to the serotonergic system
RU2002128010A (en) DRUGS FOR ORAL ADMINISTRATION WITH SLOW-RELEASE
EP0761209A3 (en) Controlled release formulations of ranitidine
WO2002017877A3 (en) Controlled release pharmaceutical pellet compositions for reducing side effects of drugs
US6099860A (en) Controlled release oral preparation with naproxen sodium and pseudoephedrine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PH PL RO RU SG SI SK SL TR TT UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2003-500452

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2001995688

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 155855

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003/03915

Country of ref document: ZA

Ref document number: 526014

Country of ref document: NZ

Ref document number: 200303915

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002226371

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 03047109

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2436692

Country of ref document: CA

Ref document number: 1020037007555

Country of ref document: KR

Ref document number: 6942003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 018201792

Country of ref document: CN

Ref document number: 2002547535

Country of ref document: JP

Ref document number: PA/a/2003/005099

Country of ref document: MX

Ref document number: 899/CHENP/2003

Country of ref document: IN

Ref document number: PV2003-1589

Country of ref document: CZ

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 2001995688

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-1589

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020037007555

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2003-1589

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001995688

Country of ref document: EP